Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
10:32am, Friday, 17'th Nov 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
3 Industry Titans Benefitting from Mega Trends
03:47pm, Thursday, 16'th Nov 2023
What do stretchy pants, fat-loss drugs, and sports betting have in common? Each of these is powering some of the strongest mega-trends on Wall Street.
Novo Nordisk Eyes Another Breakout As Weight-Loss Battle Continues
12:48pm, Thursday, 16'th Nov 2023
Novo Nordisk stock is Thursday's IBD Stock Of The Day after a study showed weight-loss drug, Wegovy, cut down on heart attacks and strokes.
Weight loss drugs and stocks: Breaking down the GLP1 market for investors
11:42am, Thursday, 16'th Nov 2023
Weight loss drugs are at the forefront of demand in the pharmaceutical sector as major drug manufacturers Novo Nordisk (NVO) and Lilly (LLY) undergoing clinical trials for new GLP-1 drugs. And, one an
Investors increase holdings of weight-loss drug makers' shares in Q3 -filings
06:46pm, Tuesday, 14'th Nov 2023
Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filin
Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds
03:34pm, Tuesday, 14'th Nov 2023
For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.
Wegovy's Sales Potential Could Go Far Beyond Just Weight-Loss Treatment
11:37am, Tuesday, 14'th Nov 2023
Wegovy is approved to treat chronic weight management, but it has far more potential in the future. Another indication, for reducing the risk of cardiovascular disease, could be coming in 2024.
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
10:00am, Tuesday, 14'th Nov 2023
Nvidia is leading the artificial intelligence revolution, and that's not likely to change. The world will always need new drugs, and Icon can help bring them to market.
Belgium bans use of Ozempic for weight loss until summer
09:50am, Tuesday, 14'th Nov 2023
Belgium has decided to temporarily ban the use of Novo Nordisk's diabetes drug Ozempic as a weight loss treatment amid a shortage of the medicine, according to a royal decree published in the country'
Better Growth Stock: Pfizer vs. Novo Nordisk
09:45am, Tuesday, 14'th Nov 2023
Pfizer is looking to buy and develop new revenue drivers. Novo Nordisk aims to penetrate a profitable market even more.
Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs
07:47pm, Monday, 13'th Nov 2023
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
07:04pm, Monday, 13'th Nov 2023
CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.
How Novo Nordisk's ‘select' study results could shake up the obesity drug space
07:04pm, Monday, 13'th Nov 2023
Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk's ‘select' study and what it means for the obesity drug space.
Novo Nordisk ADRs Climb After Study Suggests Its Wegovy Showed Heart Benefits
01:15pm, Monday, 13'th Nov 2023
American depositary receipts (ADRs) of Novo Nordisk (NVO) edged higher in early trading on Monday after reporting a study showed its flagship diabetes and weight-loss drug, Wegovy, helped reduce risks
Novo Nordisk Stock Skids — But These Weight-Loss Results Are 'Hard To Ignore'
12:22pm, Monday, 13'th Nov 2023
Novo Nordisk stock slumped Monday despite unveiling promising test results for weight-loss drugs and diabetes development.
